Poor Outcome for Rotor Ablation in A-Fib in Randomized Trial

Share this content:
Poor Outcome for Rotor Ablation in A-Fib in Randomized Trial
Poor Outcome for Rotor Ablation in A-Fib in Randomized Trial

MONDAY, May 9, 2016 (HealthDay News) -- For patients with non-paroxysmal atrial fibrillation (AF), rotor-only ablation is associated with a poor outcome compared with other ablation strategies, according to a randomized study published online May 6 in the Journal of the American College of Cardiology. The research was published to coincide with the annual meeting of the Heart Rhythm Society, held from May 4 to 7 in San Francisco.

Sanghamitra Mohanty, M.D., from St. David's Medical Center in Austin, Texas, and colleagues randomized non-paroxysmal AF patients undergoing first ablation to focal impulse and rotor modulation (FIRM)-guided ablation only (group 1; 29 patients), FIRM + pulmonary vein antrum isolation (PVAI) (group 2; 42 patients), or PVAI + posterior wall + non-PV trigger ablation (group 3; 42 patients).

The researchers terminated enrollment in group 1 early for futility. Procedure time was significantly shorter in group 3 versus groups 1 and 2 (P < 0.001). Acute success after rotor-only ablation was achieved in 41 and 26 percent of patients in groups 1 and 2, respectively. Overall, 14, 52.4, and 76.0 percent of patients in groups 1, 2, and 3 were AF/atrial tachycardia-free off anti-arrhythmic drugs after 12 ± 7-month follow-up (log-rank P < 0.0001). Compared with groups 1 and 2, group 3 patients experienced higher success.

"This is the first randomized study that compared three ablation strategies in non-paroxysmal AF patients and reported a very poor outcome with rotor-only ablation," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

Full Text (subscription or payment may be required)
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »